semaglutide for sleep apnea 📊 New late-stage clinical trial results show an investigational Lilly medicine reduced moderate-to-severe obstructive severity by an average 61 percent in adults living with obesity and OSA on the 9 glp-1 approved for sleep apnea

6.2 Novo Nordisk + Septerna (May 2025, up to $2.2B) Novo's second major triple-agonist transaction was a broader small-molecule GPCR collaboration with Septerna announced May 2025: up to $2.2 billion total deal value, $200 million+ upfront, covering four oral small-molecule GPCR programs

We also look into how these choices are backed by science and where the evidence gap exists

Treatment Monitoring

Understanding why they are fundamentally different helps set appropriate expectations

If cost is a concern, you may want to explore FDA-approved options with insurance, discounts, or assistance programs, as they may be safer and more effective in the long run

WHY THIS MATTERS FOR YOUR COVERAGE Understanding CVS Caremark as a PBM CVS Caremark is a pharmacy benefit manager (PBM) a middleman between your insurance company and pharmacies